<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To assess the effect of dietary <z:chebi fb="5" ids="47916">flavonoids</z:chebi> on <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) risk in postmenopausal women with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> on established <z:chebi fb="0" ids="35664">statin</z:chebi> and hypoglycemic therapy </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Despite being medicated, patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> have elevated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk, particularly postmenopausal women </plain></SENT>
<SENT sid="2" pm="."><plain>Although dietary <z:chebi fb="5" ids="47916">flavonoids</z:chebi> have been shown to reduce <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk factors in healthy participants, no long-term trials have examined the additional benefits of <z:chebi fb="5" ids="47916">flavonoids</z:chebi> to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk in medicated postmenopausal women with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We conducted a parallel-design, placebo-controlled trial with type 2 diabetic patients randomized to consume 27 g/day (split dose) <z:chebi fb="5" ids="47916">flavonoid</z:chebi>-enriched chocolate (containing 850 mg <z:chebi fb="0" ids="38691">flavan</z:chebi>-3-ols [90 mg epicatechin] and 100 mg <z:chebi fb="0" ids="18220">isoflavones</z:chebi> [aglycone equivalents)]/day) or matched placebo for 1 year </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Ninety-three patients completed the trial, and adherence was high (<z:chebi fb="5" ids="47916">flavonoid</z:chebi> 91.3%; placebo 91.6%) </plain></SENT>
<SENT sid="5" pm="."><plain>Compared with the placebo group, the combined <z:chebi fb="5" ids="47916">flavonoid</z:chebi> intervention resulted in a significant reduction in estimated peripheral <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (homeostasis model assessment of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> [HOMA-IR] -0.3 ± 0.2; P = 0.004) and improvement in insulin sensitivity (quantitative insulin sensitivity index [QUICKI] 0.003 ± 0.00; P = 0.04) as a result of a significant decrease in insulin levels (-0.8 ± 0.5 mU/L; P = 0.02) </plain></SENT>
<SENT sid="6" pm="."><plain>Significant reductions in total cholesterol:<z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>) ratio (-0.2 ± 0.1; P = 0.01) and <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>) (-0.1 ± 0.1 mmol/L; P = 0.04) were also observed </plain></SENT>
<SENT sid="7" pm="."><plain>Estimated 10-year total <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> risk (derived from UK Prospective <z:mp ids='MP_0002055'>Diabetes</z:mp> Study algorithm) was attenuated after <z:chebi fb="5" ids="47916">flavonoid</z:chebi> intervention (<z:chebi fb="5" ids="47916">flavonoid</z:chebi> +0.1 ± 0.3 vs. placebo 1.1 ± 0.3; P = 0.02) </plain></SENT>
<SENT sid="8" pm="."><plain>No effect on blood pressure, HbA(1c), or <z:chebi fb="105" ids="17234">glucose</z:chebi> was observed </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: One-year intervention with <z:chebi fb="0" ids="38691">flavan</z:chebi>-3-ols and <z:chebi fb="0" ids="18220">isoflavones</z:chebi> improved biomarkers of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk, highlighting the additional benefit of <z:chebi fb="5" ids="47916">flavonoids</z:chebi> to standard drug therapy in managing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk in postmenopausal type 2 diabetic patients </plain></SENT>
</text></document>